European Surgical Research
Original Paper
Systemic and Local Cytokine Kinetics after Total Hip Replacement SurgeryBastian D.a · Tamburstuen M.V.b · Lyngstadaas S.P.b · Reikerås O.aaDepartment of Orthopaedics and bInstitute for Clinical Dentistry, Rikshospitalet University Clinic, University of Oslo, Oslo, Norway
|
|
Eur Surg Res 2008;41:334–340
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
First-Page Preview
Received: April 22, 2008
Accepted: June 24, 2008
Published online: September 25, 2008
Issue release date: November 2008
Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 2
ISSN: 0014-312X (Print)
eISSN: 1421-9921 (Online)
For additional information: https://www.karger.com/ESR
Abstract
Background: Trauma induces local and subsequent systemic inflammatory reactions. Aberrant reactions can lead to a systemic inflammatory response syndrome, with a potentially lethal outcome. Our aim was to investigate the early local cytokine kinetic compared to systemic changes in a standardized surgical trauma. Methods: In 7 patients with total hip replacement, drained blood samples and venous blood samples were taken 3 times within the first day after the operation. Interleukin (IL) release was assessed by a multiplex antibody bead kit and compared to pre-operative values. Results: The major findings were significant increases in systemic levels of IL-6 and in local levels of IL-6, IL-8 and IL-1 receptor antagonist (IL-1Ra), and that the local levels of these cytokines were significantly higher than the systemic ones after surgery. Besides, there were only modest changes in local and systemic levels of tumour necrosis factor α, IL-1β, IL-2, IL-2Ra, IL-4, IL-5, IL-7, IL-10, IL-12, IL-13, IL-15 and IL-17. Conclusions: The acute sterile inflammation after major orthopaedic surgery is principally characterized by significantly increased local and systemic levels of IL-6 and significantly increased local levels of IL-8 and IL-1Ra. Furthermore, the concentrations are higher at the local site of injury. Hence, we conclude that systemic cytokine levels might not reflect local reactions.
© 2008 S. Karger AG, Basel
Related Articles:
References
- Gharaee-Kermani M, Phan SH: Role of cytokines and cytokine therapy in wound healing and fibrotic diseases. Curr Pharm Des 2001;7:1083–1103.
- Bastian D, Shegarfi H, Rolstad B, Naper C, Lyngstadaas SP, Reikeras O: Investigation of lipopolysaccharide receptor expression on human monocytes after major orthopaedic surgery. Eur Surg Res 2007;40:239–245.
- Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996;24:1125–1128.
- Baumann H, Gauldie J: The acute phase response. Immunol Today 1994;15:74–80.
- Haziot A, Rong GW, Lin XY, Silver J, Goyert SM: Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol 1995;154:6529–6532.
- Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990;348:550–552.
- Deans KJ, Haley M, Natanson C, Eichacker PQ, Minneci PC: Novel therapies for sepsis: a review. J Trauma 2005;58:867–874.
- Fisher CJ, Agosti JM, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996;334:1697–1702.
- Skaga NO, Eken T, Sovik S, Jones JM, Steen PA: Pre-injury ASA physical status classification is an independent predictor of mortality after trauma. J Trauma 2007;63:972–978.
- Dalen T, Engstrom KG: Microrheology of filtered autotransfusion drain blood with and without leukocyte reduction. Clin Hemorheol Microcirc 1999;21:113–123.
-
Kvarnstrom A, Schmidt A, Tylman M, Jacobsson M, Bengtsson A: Complement split products and proinflammatory cytokines in intraoperatively salvaged unwashed blood during hip replacement: comparison between heparin-coated and non-heparin-coated autotransfusion systems. Vox Sang 2008, E-pub ahead of print.
- Dinarello CA: Proinflammatory cytokines. Chest 2000;118:503–508.
- Dimofte G, Alexander A, Carlson G, Little R, Irving M: TNF alpha and IL-6 involvement in surgical trauma. II. In vitro cytokine production. Rev Med Chir Soc Med Nat Iasi 2001;105:493–498.
- Menger MD, Vollmar B: Surgical trauma: hyperinflammation versus immunosuppression? Langenbecks Arch Surg 2004;389:475–484.
- Ramadori G, Sipe JD, Dinarello CA, Mizel SB, Colten HR: Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1. J Exp Med 1985;162:930–942.
- Pape HC, Schmidt RE, Rice J, et al: Biochemical changes after trauma and skeletal surgery of the lower extremity: quantification of the operative burden. Crit Care Med 2000;28:3441–3448.
- Sakamoto K, Arakawa H, Mita S, et al: Elevation of circulating interleukin 6 after surgery: factors influencing the serum level. Cytokine 1994;6:181–186.
- Perregaux D, Gabel CA: Interleukin-1 beta maturation and release in response to ATP and nigericin: evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J Biol Chem 1994;269:15195–203.
- Perregaux DG, Gabel CA: Post-translational processing of murine IL-1: evidence that ATP-induced release of IL-1 alpha and IL-1 beta occurs via a similar mechanism. J Immunol 1998;160:2469–2477.
- Horn F, Henze C, Heidrich K: Interleukin-6 signal transduction and lymphocyte function. Immunobiology 2000;202:151–167.
- Ramadori G, Christ B: Cytokines and the hepatic acute-phase response. Semin Liver Dis 1999;19:141–155.
- Reikeraas O, Sun J, Krohn CD, Wang JE, Aasen AO: Reduced capacity of whole blood leucocytes to express tumour necrosis factor-alpha and interleukin-10 following major orthopaedic surgery. Eur Surg Res 2005;37:210–215.
- Biffl WL, Moore EE, Moore FA, Peterson VM: Interleukin-6 in the injured patient: marker of injury or mediator of inflammation? Ann Surg 1996;224:647–664.
- Shenkin A, Fraser WD, Series J, et al: The serum interleukin 6 response to elective surgery. Lymphokine Res 1989;8:123–127.
- Cruickshank AM, Fraser WD, Burns HJ, Van DJ, Shenkin A: Response of serum interleukin-6 in patients undergoing elective surgery of varying severity. Clin Sci (Lond) 1990;79:161–165.
- Baigrie RJ, Lamont PM, Kwiatkowski D, Dallman MJ, Morris PJ: Systemic cytokine response after major surgery. Br J Surg 1992;79:757–760.
- Fey GH, Fuller GM: Regulation of acute phase gene expression by inflammatory mediators. Mol Biol Med 1987;4:323–338.
- Kaibara A, Espat NJ, Auffenberg T, et al: Interleukin 6, but not ciliary neutrotrophic factor or leukaemia inhibitory factor, is responsible for the acute phase response to turpentine-induced myositis. Cytokine 1998;10:452–456.
- Tilg H, Dinarello CA, Mier JW: IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today 1997;18:428–432.
- Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW: Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994;83:113–118.
- Steensberg A, Fischer CP, Keller C, Moller K, Pedersen BK: IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab 2003;285:E433–E437.
- Yager DR, Kulina RA, Gilman LA: Wound fluids: a window into the wound environment? Int J Low Extrem Wounds 2007;6:262–272.
- Sheeran P, Hall GM: Cytokines in anaesthesia. Br J Anaesth 1997;78:201–219.
- Mokart D, Capo C, Blache JL, et al: Early postoperative compensatory anti-inflammatory response syndrome is associated with septic complications after major surgical trauma in patients with cancer. Br J Surg 2002;89:1450–1456.
- Smith KA: Interleukin-2: inception, impact, and implications. Science 1988;240:1169–1176.
- Sanarico N, Ciaramella A, Sacchi A, et al: Human monocyte-derived dendritic cells differentiated in the presence of IL-2 produce proinflammatory cytokines and prime Th1 immune response. J Leukoc Biol 2006;80:555–562.
- Moore KW, de Waal MR, Coffman RL, O’Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683–765.
- Muehlstedt SG, Richardson CJ, Lyte M, Rodriguez JL: Systemic and pulmonary effector cell function after injury. Crit Care Med 2002;30:1322–1326.
- Randolph GJ, Furie MB: A soluble gradient of endogenous monocyte chemoattractant protein-1 promotes the transendothelial migration of monocytes in vitro. J Immunol 1995;155:3610–3618.
- Sekido N, Mukaida N, Harada A, Nakanishi I, Watanabe Y, Matsushima K: Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature 1993;365:654–657.
- Tsukada K, Omert LA, Menezes J, et al: Neutrophil accumulation and damage to the gastric mucosa in resuscitated hemorrhagic shock is independent of inducible nitric oxide synthase. Shock 1999;11:319–324.
- Gordon JR, Li F, Zhang X, Wang W, Zhao X, Nayyar A: The combined CXCR1/CXCR2 antagonist CXCL8(3–74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals. J Leukoc Biol 2005;78:1265–1272.
- Andersson I, Tylman M, Bengtson JP, Bengtsson A: Complement split products and pro-inflammatory cytokines in salvaged blood after hip and knee arthroplasty. Can J Anesth 2001;48:251–255.
- Bjornsson GL, Thorsteinsson L, Gudmundsson KO, Jonsson H Jr, Gudmundsson S, Gudbjornsson B: Inflammatory cytokines in relation to adrenal response following total hip replacement. Scand J Immunol 2007;65:99–105.
Article / Publication Details
First-Page Preview
Received: April 22, 2008
Accepted: June 24, 2008
Published online: September 25, 2008
Issue release date: November 2008
Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 2
ISSN: 0014-312X (Print)
eISSN: 1421-9921 (Online)
For additional information: https://www.karger.com/ESR
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
